Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of StockholdersGlobeNewsWire • 12/06/23
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ LeukemiaGlobeNewsWire • 12/04/23
GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual MeetingGlobeNewsWire • 11/06/23
GT Biopharma, Inc. (GTBP) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 08/24/23
GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023GlobeNewsWire • 08/03/23
Here's Why GT Biopharma, Inc. (GTBP) Is a Great 'Buy the Bottom' Stock NowZacks Investment Research • 06/02/23
All You Need to Know About GT Biopharma, Inc. (GTBP) Rating Upgrade to BuyZacks Investment Research • 05/19/23
GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/15/23
GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/30/23
GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual ConferenceGlobeNewsWire • 02/24/23
GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To MarketGlobeNewsWire • 12/30/22
GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022GlobeNewsWire • 12/12/22
GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer's (SITC) 37th Annual MeetingGlobeNewsWire • 11/10/22
GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual MeetingGlobeNewsWire • 11/03/22
GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results and Business UpdateGlobeNewsWire • 10/31/22
GT Biopharma Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 37th Annual MeetingGlobeNewsWire • 10/06/22